Literature DB >> 26912307

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide Study.

Yin-Kai Chao1, Hui-Shan Chen2, Bing-Yen Wang3, Po-Kuei Hsu4, Chia-Chuan Liu5, Shiao-Chi Wu2.   

Abstract

BACKGROUND: Few data are available on the survival outcomes of patients with esophageal squamous cell carcinoma who achieve complete response at the primary site but have residual nodal metastases after chemoradiotherapy. We sought to assess the survival of esophageal squamous cell carcinoma patients with ypT0 N+ disease.
METHODS: Esophageal squamous cell carcinoma patients treated with chemoradiotherapy and esophagectomy were identified from the Taiwan Cancer Registry between 2008 and 2013. We compared the clinical and survival data of ypT0 N+ and ypT0 N0 patients. The median number of dissected nodes (n = 20) was used as the cutoff to classify the extent of lymph node dissection (LND). Survival data were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models.
RESULTS: The study included 369 ypT0 patients (50 ypT0 N+ [13.6%] and 319 ypT0 N0 [86.4%]). The 3-year overall survival was significantly lower in ypT0 N+ patients (30.1%) than in ypT0 N0 patients (55.9%, p < 0.001). Multivariate analysis showed that a higher number of positive lymph nodes (ypN2/N3 vs ypN1) was a strong adverse prognostic factor (hazard ratio, 3.76; p = 0.011) in ypT0 N+ patients. The extent of LND was identified as an independent predictor of survival in patients with ypT0 N0 disease (low vs high; hazard ratio, 1.49; p = 0.045). A stepwise decrease in 3-year overall survival rates was observed in the following groups: ypT0 N0 with high LND (61.2%), ypT0 N0 with low LND (50.3%), and ypT0 N+ (30.1%, p < 0.001).
CONCLUSIONS: At least 13.6% of ypT0 patients have lymph node metastases, which carry adverse prognostic implications. The number of positive nodes is the most important prognostic factor in this group.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26912307     DOI: 10.1016/j.athoracsur.2015.11.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.

Authors:  Yoichi Hamai; Jun Hihara; Manabu Emi; Takaoki Furukawa; Yuji Murakami; Ikuno Nishibuchi; Yuta Ibuki; Ichiko Yamakita; Tomoaki Kurokawa; Yasushi Nagata; Morihito Okada
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

2.  Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy.

Authors:  Chen-Sung Lin; Chao-Yu Liu; Chih-Tao Cheng; Yu-Chen Tsai; Lun-Wei Chiou; Ming-Yuan Lee; Chia-Chuan Liu; Chih-Hsun Shih
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Safety and oncological efficacy of bilateral recurrent laryngeal nerve lymph-node dissection after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a propensity-matched analysis.

Authors:  Yin-Kai Chao; Chien-Hung Chiu; Yun-Hen Liu
Journal:  Esophagus       Date:  2019-08-19       Impact factor: 4.230

4.  ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?

Authors:  Lieven Peter Depypere; Gil Vervloet; Toni Lerut; Johnny Moons; Gert De Hertogh; Xavier Sagaert; Willy Coosemans; Hans Van Veer; Philippe Robert Nafteux
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.

Authors:  Xiaobin Zhang; Ben M Eyck; Yang Yang; Jun Liu; Yin-Kai Chao; Ming-Mo Hou; Tsung-Min Hung; Qingsong Pang; Zhen-Tao Yu; Hongjing Jiang; Simon Law; Ian Wong; Ka-On Lam; Berend J van der Wilk; Ate van der Gaast; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot; Zhigang Li
Journal:  BMC Cancer       Date:  2020-03-06       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.